Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of teicoplanin in preparation of drugs for Middle East respiratory syndrome coronavirus

A technology for respiratory syndrome and teicoplanin, applied in the direction of antiviral agents, glycopeptide components, etc., can solve the problems of no antiviral drugs, lack of vaccines and drugs, etc., and achieve the effect of avoiding a long cycle

Active Publication Date: 2015-10-07
SUN YAT SEN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the world still lacks effective vaccines and drugs against MERS-CoV
Currently, there are no ready-made antiviral drugs on the market for MERS-CoV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of teicoplanin in preparation of drugs for Middle East respiratory syndrome coronavirus
  • Application of teicoplanin in preparation of drugs for Middle East respiratory syndrome coronavirus
  • Application of teicoplanin in preparation of drugs for Middle East respiratory syndrome coronavirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 The inhibitory effect of different concentrations of the compound antibiotic teicoplanin on the envelope protein S of Middle East respiratory syndrome coronavirus (MERS-CoV)

[0038] (1) Packaged virus: 4.5 μg pHIV-luciferase, 4.5 μg pCMV-ΔR8.2 and 10 μg MERS-CoV-S plasmids were transfected into 293T cells (10 cm dish). After 48 hours, the virus supernatant was collected and assayed. p24.

[0039] (2) Compound screening against MERS-CoV-S: Infect 293T cells in a 96-well plate with p24-normalized MERS-CoV-S pseudovirus supernatant (containing 8 μg / ml Polybrene) Lanin compounds.

[0040] (3) Change medium: 12 hours after infection, replace with fresh DMEM medium.

[0041] (4) Detection of luciferase activity: 48 hours after infection, each well was washed once with PBS, then 100 μl of lysate was added, shaken for 30 min, and 10 μl of lysate was taken to detect luciferase activity.

[0042] According to the result of Example 1 figure 1 It shows that the antib...

Embodiment 2

[0043] Example 2 The inhibitory effect of different concentrations of the compound antibiotic teicoplanin on the envelope of vesicular stomatitis virus VSV-G

[0044] (1) Package virus: 4.5 μg pHIV-luciferase, 4.5 μg pCMV-ΔR8.2 and 10 μg VSV-G plasmids were transfected into 293T cells (10 cm dish). After 48 hours, the virus supernatant was collected and p24 was measured.

[0045] (2) Compound screening against VSV-G: Infect 293T cells in a 96-well plate with p24-normalized VSV-G pseudovirus supernatant (containing 8 μg / ml Polybrene), and add different concentrations of teicoplanin compound at the same time.

[0046] (3) Change medium: 12 hours after infection, replace with fresh DMEM medium.

[0047] (4) Detection of luciferase activity: 48 hours after infection, each well was washed once with PBS, then 100 ul of lysate was added, shaken for 30 minutes, and 10 ul of lysate was taken to detect luciferase activity.

[0048] According to the result of Example 2 figure 2 It sho...

Embodiment 3

[0049] Example 3 The inhibitory effect of different concentrations of the compound antibiotic teicoplanin on the envelope protein S of severe acute respiratory syndrome coronavirus (SARS-CoV)

[0050] (1) Packaged virus: 6.5 μg pHIV-luciferase, 8 μg pCMV-ΔR8.2 and 20 μg SARS-CoV-S plasmid were transfected into 293T cells (10 cm dish). After 48 hours, the virus supernatant was collected and assayed. p24.

[0051] (2) Compound screening against SARS-CoV-S: Infect 293T cells in a 96-well plate with the p24-normalized SARS-CoV-S pseudovirus supernatant (containing 8 μg / ml Polybrene), and add different concentrations of Tetrapyrene Lanin compounds.

[0052] (3) Change medium: 12 hours after infection, replace with fresh DMEM medium.

[0053] (4) Detection of luciferase activity: 48 hours after infection, each well was washed once with PBS, then 100 μl of lysate was added, shaken for 30 min, and 10 μl of lysate was taken to detect luciferase activity.

[0054] According to the resu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of teicoplanin in preparation of drugs for MERS-CoV (Middle East respiratory syndrome coronavirus). According to the application, teicoplanin compounds have the effect of treating the MERS-CoV in vitro.

Description

technical field [0001] The present invention relates to the new application of antiviral drugs, more specifically, relates to the preparation of a teicoplanin compound against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) application in medicine. Background technique [0002] Middle East respiratory syndrome is an acute respiratory disease caused by a new coronavirus discovered in 2012. On May 23, 2013, the World Health Organization named this new coronavirus infection "Middle East respiratory syndrome". The virus first appeared in Saudi Arabia, and then spread to other countries in the Middle East and Europe. In early 2015, the first confirmed case was reported in South Korea, which caused further spread. On May 29, according to the report of my country's National Health and Family Planning Commission, the first confirmed case of imported Middle East Respiratory Syndrome appeared in Huizhou City, Guang...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/14A61P31/14
Inventor 潘婷周南张辉
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com